These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22059385)

  • 1. Inhibition mechanism of human galectin-7 by a novel galactose-benzylphosphate inhibitor.
    Masuyer G; Jabeen T; Öberg CT; Leffler H; Nilsson UJ; Acharya KR
    FEBS J; 2012 Jan; 279(2):193-202. PubMed ID: 22059385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzimidazole-galactosides bind selectively to the Galectin-8 N-Terminal domain: Structure-based design and optimisation.
    Hassan M; van Klaveren S; Håkansson M; Diehl C; Kovačič R; Baussière F; Sundin AP; Dernovšek J; Walse B; Zetterberg F; Leffler H; Anderluh M; Tomašič T; Jakopin Ž; Nilsson UJ
    Eur J Med Chem; 2021 Nov; 223():113664. PubMed ID: 34225180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzymatic synthesis of non-natural trisaccharides and galactosides; Insights of their interaction with galectins as a function of their structure.
    Porciúncula González C; Cagnoni AJ; Mariño KV; Fontana C; Saenz-Méndez P; Irazoqui G; Giacomini C
    Carbohydr Res; 2019 Jan; 472():1-15. PubMed ID: 30428394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of multivalent galactose-based dendrimer recognition by human galectin-7.
    Ramaswamy S; Sleiman MH; Masuyer G; Arbez-Gindre C; Micha-Screttas M; Calogeropoulou T; Steele BR; Acharya KR
    FEBS J; 2015 Jan; 282(2):372-87. PubMed ID: 25367374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors.
    Hsieh TJ; Lin HY; Tu Z; Lin TC; Wu SC; Tseng YY; Liu FT; Hsu ST; Lin CH
    Sci Rep; 2016 Jul; 6():29457. PubMed ID: 27416897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin.
    Vladoiu MC; Labrie M; Létourneau M; Egesborg P; Gagné D; Billard É; Grosset AA; Doucet N; Chatenet D; St-Pierre Y
    Oncotarget; 2015 Dec; 6(38):40970-80. PubMed ID: 26543238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Design of a Monosaccharide Ligand Targeting Galectin-8.
    Bohari MH; Yu X; Kishor C; Patel B; Go RM; Eslampanah Seyedi HA; Vinik Y; Grice ID; Zick Y; Blanchard H
    ChemMedChem; 2018 Aug; 13(16):1664-1672. PubMed ID: 29926535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X-ray structure of a protease-resistant mutant form of human galectin-9 having two carbohydrate recognition domains with a metal-binding site.
    Yoshida H; Nishi N; Wada K; Nakamura T; Hirashima M; Kuwabara N; Kato R; Kamitori S
    Biochem Biophys Res Commun; 2017 Sep; 490(4):1287-1293. PubMed ID: 28687490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model.
    Stannard KA; Collins PM; Ito K; Sullivan EM; Scott SA; Gabutero E; Darren Grice I; Low P; Nilsson UJ; Leffler H; Blanchard H; Ralph SJ
    Cancer Lett; 2010 Dec; 299(2):95-110. PubMed ID: 20826047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-13, a different prototype galectin, does not bind β-galacto-sides and forms dimers via intermolecular disulfide bridges between Cys-136 and Cys-138.
    Su J; Wang Y; Si Y; Gao J; Song C; Cui L; Wu R; Tai G; Zhou Y
    Sci Rep; 2018 Jan; 8(1):980. PubMed ID: 29343868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting the Structure-Activity Relationship of Galectin-Ligand Interactions.
    Chan YC; Lin HY; Tu Z; Kuo YH; Hsu SD; Lin CH
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.
    Rajput VK; MacKinnon A; Mandal S; Collins P; Blanchard H; Leffler H; Sethi T; Schambye H; Mukhopadhyay B; Nilsson UJ
    J Med Chem; 2016 Sep; 59(17):8141-7. PubMed ID: 27500311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinoline-galactose hybrids bind selectively with high affinity to a galectin-8 N-terminal domain.
    Pal KB; Mahanti M; Huang X; Persson S; Sundin AP; Zetterberg FR; Oredsson S; Leffler H; Nilsson UJ
    Org Biomol Chem; 2018 Aug; 16(34):6295-6305. PubMed ID: 30117507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the Molecular Details of the Interactions of Selenoglycosides and Human Galectin-3.
    Raics M; Balogh ÁK; Kishor C; Timári I; Medrano FJ; Romero A; Go RM; Blanchard H; Szilágyi L; E Kövér K; Fehér K
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affinity of galectin-8 and its carbohydrate recognition domains for ligands in solution and at the cell surface.
    Carlsson S; Oberg CT; Carlsson MC; Sundin A; Nilsson UJ; Smith D; Cummings RD; Almkvist J; Karlsson A; Leffler H
    Glycobiology; 2007 Jun; 17(6):663-76. PubMed ID: 17339281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of galectins with small molecules.
    Oberg CT; Leffler H; Nilsson UJ
    Chimia (Aarau); 2011; 65(1-2):18-23. PubMed ID: 21469439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saturation Transfer Difference NMR and Molecular Docking Interaction Study of Aralkyl-Thiodigalactosides as Potential Inhibitors of the Human-Galectin-3 Protein.
    Hőgye F; Farkas LB; Balogh ÁK; Szilágyi L; Alnukari S; Bajza I; Borbás A; Fehér K; Illyés TZ; Timári I
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient synthesis of a galectin inhibitor clinical candidate (TD139) using a Payne rearrangement/azidation reaction cascade.
    St-Gelais J; Denavit V; Giguère D
    Org Biomol Chem; 2020 May; 18(20):3903-3907. PubMed ID: 32400847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regioselective 3-O-Substitution of Unprotected Thiodigalactosides: Direct Route to Galectin Inhibitors.
    Vašíček T; Spiwok V; Červený J; Petrásková L; Bumba L; Vrbata D; Pelantová H; Křen V; Bojarová P
    Chemistry; 2020 Aug; 26(43):9620-9631. PubMed ID: 32368810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human galectin-3 selective and high affinity inhibitors. Present state and future perspectives.
    Téllez-Sanz R; García-Fuentes L; Vargas-Berenguel A
    Curr Med Chem; 2013; 20(24):2979-90. PubMed ID: 23834183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.